Predict your next investment

dan-inno.dk

See what CB Insights has to offer

Investments

4

Portfolio Exits

1

About Dansk Innovationsinvestering

Dansk Innovationsinvestering Headquarter Location

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Dansk Innovationsinvestering

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find Dansk Innovationsinvestering in 3 Expert Collections, including Synthetic Biology.

S

Synthetic Biology

382 items

P

Pharma Startups

5,090 items

Pharmaceutical companies working across drug discovery, drug development and drug manufacturing.

I

Industrial SynBio

382 items

Synthetic biology focused on replacing industrial and commercial materials.

Latest Dansk Innovationsinvestering News

Evolva raises € 12 million A-round from International Investors

Mar 26, 2015

Evolva Biotech today announced that it has raised c. € 12 million (CHF 18.5 million, Dkr 90 million, US $ 14.9 million) of equity financing in a first-closing of its A-round. The financing was led by Aravis and included new investors Novartis Venture Fund, Yamanouchi Venture Capital and Dansk Innovationsinvestering. Existing investors Symbion Capital and Vaekstfonden also participated. In connection to the financing Evolva is establishing operations in Basel, Switzerland. Neil Goldsmith, Managing Director of Evolva, said “We are pleased that we have succeeded in attracting high quality international investors to Evolva. The Aravis team has a tremendous track-record in backing future leaders of the biotech industry at an early stage. The presence of the venture capital arms of two major pharmaceutical companies speaks for itself. The financing environment for early stage biotechnology platforms remains difficult. We thus see this as an important endorsement of our Watchmaker® technology platform and our achievements to date” Jean-Philippe Tripet, Managing Partner of Aravis, commented that. “Evolva is opening a new field in the evolution of pharmaceuticals and addresses a major bottleneck in the discovery of novel drugs of natural origin. We believe that the establishment of an operation in Switzerland will enable Evolva to recruit key personnel and get closer to a network of large pharmaceutical companies. Aravis as lead investor will provide active advice to ensure that Evolva rapidly reaches a high level of maturity and becomes a commercial success,” Trine Wintero, COO of Symbion Capital (Evolva’s founding seed investor) said. “This is excellent news for Evolva. It proves that good teams and good technologies can attract strong international investors. Symbion Capital is pleased to be working together with such recognized investors and looks forward to bringing Evolva and Watchmaker® to the attention of international biotech and pharmaceutical companies.” About Evolva Evolva evolves small molecule drugs using massively combinatorial gene libraries that drive chemistry rich pathways. Its Watchmaker® technology platform replicates, on an industrial basis, the ability of nature to evolve molecules with exquisite “design”, but with the evolution directly aimed at making functional drugs - HIV blockers, anti-obesity compounds etc. Watchmaker® can create, optimise and manufacture molecules that are outside the scope of the traditional synthetic chemistry approaches of the industry. About Aravis Aravis, founded in 2002, is an international venture capital group focusing on early-stage Biotech companies with offices in Zurich, Switzerland and Menlo Park, California. The Aravis investment team is comprised of 14 partners, investment experienced leading scientists, venture capitalists and operating executives who have been involved with the successful financing, growth and realization of more than 80 Biotech companies worldwide over the last 15 years. With the combined know how of scientific expertise and management, Aravis seeks to add value to its investments by actively participating in the buildup and growth of its Portfolio Companies. Contact Details

Dansk Innovationsinvestering Investments

4 Investments

Dansk Innovationsinvestering has made 4 investments. Their latest investment was in Vivostat as part of their Unattributed VC on February 2, 2007.

CBI Logo

Dansk Innovationsinvestering Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

2/5/2007

Unattributed VC

Vivostat

$9.3M

Yes

1

8/16/2004

Series A

Subscribe to see more

$99M

Subscribe to see more

10

Other Investors

Subscribe to see more

$99M

Subscribe to see more

10

Other Investors

Subscribe to see more

$99M

Subscribe to see more

10

Date

2/5/2007

8/16/2004

Round

Unattributed VC

Series A

Other Investors

Other Investors

Company

Vivostat

Subscribe to see more

Subscribe to see more

Subscribe to see more

Amount

$9.3M

$99M

$99M

$99M

New?

Yes

Subscribe to see more

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

1

10

10

10

Dansk Innovationsinvestering Portfolio Exits

1 Portfolio Exit

Dansk Innovationsinvestering has 1 portfolio exit. Their latest portfolio exit was Evolva Holding on December 01, 2009.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

12/1/2009

Reverse Merger

2

Date

12/1/2009

Exit

Reverse Merger

Companies

Valuation

Acquirer

Sources

2

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.